Does Colossal Biosciences’ dire wolf creation justify its $10B+ valuation?

On Monday, the “de-extinction” startup Colossal Biosciences announced its most ambitious results to date: the dire…

CRISPR Therapeutics Set To Reach Previous Heights

CRISPR Therapeutics Set To Reach Previous Heights #CRISPR #Therapeutics #Set #Reach #Previous #Heights

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future (CRSP)

This article was written by Follow Edmund Ingham is a biotech consultant. He has been covering…

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers #CRISPR #Therapeutics #Unfairly #Punished #Issues #Peers

Colossal Biosciences raises $200M at $10.2B valuation to bring back woolly mammoths

Colossal Biosciences, the company that’s famously on a mission to bring back the woolly mammoth and…

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025 (NASDAQ:CRSP)

This article was written by Follow Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and…